COMMUNIQUÉS West-GlobeNewswire

Financière de Tubize - Annual report 2025
21/03/2026
Annual Report 2025 Regulated information 21 March 2026 The board of directors of Financière de Tubize has established the 2025 annual report. This report is available on the website www.financiere-tubize.be Profit for [...]
Financière de Tubize - Rapport annuel 2025
21/03/2026
Rapport annuel 2025 Informations réglementées - 21 mars 2026 Le conseil d’administration de la Financière de Tubize a établi le rapport annuel 2025. Ce rapport est disponible sur le site internet www.financiere-tubize. [...]
Trim RX GLP-1 Weight Loss Medication Claims Evaluated: Investigating the TrimRX Treatment Options
20/03/2026
An informational report based on materials provided by MetaFit Pharma Solutions LLC detailing how the TrimRx telehealth platform presents its GLP-1 medication options, compounded and FDA-approved formulations, pricing [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
20/03/2026
PALO ALTO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Garaherb Claims Evaluated: Complete Scientific Investigation of Ingredients' Effectiveness
20/03/2026
An informational report compiling GaraHerb's publicly available product materials, ingredient-level research references, formulation transparency considerations, and consumer details for 2026 Aurora, CO, March 20, 2026 [...]
Publication relating to transparency notifications
20/03/2026
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
20/03/2026
BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20/03/2026
NOVATO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Purisaki Deep Cleansing Foot Pads Claims Evaluated: The 2-in-1 MultiVitamin Detox Patch for Therapeutic Support
20/03/2026
A 2026 informational overview of how Purisaki Deep Cleansing Foot Pads are described in company materials — including the 2-in-1 detoxification and vitamin infusion positioning, ingredient research context, transdermal [...]
Publication relative à des notifications de transparence
20/03/2026
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 20 mars 2026 , 22:30h CET / 17:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
20/03/2026
SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel [...]
Akemi Detox Tea Claims Evaluated: Investigating Natural Ingredients to Burn Fat and Boost Energy Support
20/03/2026
An informational report outlining how Akemi Detox Tea is presented in official materials, including ingredient research context, metabolic support positioning, and consumer considerations Elizabeth, NJ, March 20, 2026 ( [...]
XTL Biopharmaceuticals Announces ADS Ratio Change
20/03/2026
RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “ Company ” or “ XTL ”), announced today that it plans to change the ratio of its American Depositary [...]
argenx announces Annual General Meeting of Shareholders on May 6, 2026
20/03/2026
March 20, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
ReflexMD GLP-1 Claims Evaluated: Safety Risks Assessed for Reflex MD Semaglutide Telemedicine Provider
20/03/2026
An informational report based on publicly available materials from ReflexMD, Inc. — addressing how consumers evaluate GLP-1 telehealth platforms, including commonly searched topics such as platform credibility, [...]
SafeSpace Global Corporation Reports Q2 Fiscal 2026 Financial Results; Company Transitions from Pre-Revenue to Revenue-Generating Stage, Expands Footprint with Nashville Office, and Initiates Steps Toward National Exchange Uplisting
20/03/2026
KNOXVILLE, TN., March 20, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC) (SafeSpace Global or the Company), a leader in multimodal AI-powered safety and security solutions company dedicated to [...]
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
20/03/2026
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc [...]
Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results
20/03/2026
EDEN PRAIRIE, Minn., March 20, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live [...]
Disclosure of a transparency notification from Aberdeen Group plc
20/03/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen Group plc Pursuant to the Belgian act of 2 May 2007 on the [...]

Pages